Hansoh Pharmac Hd 00001 Stock Working Capital
3KY Stock | EUR 2.16 0.06 2.70% |
HANSOH PHARMAC HD 00001 fundamentals help investors to digest information that contributes to HANSOH PHARMAC's financial success or failures. It also enables traders to predict the movement of HANSOH Stock. The fundamental analysis module provides a way to measure HANSOH PHARMAC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to HANSOH PHARMAC stock.
HANSOH |
HANSOH PHARMAC HD 00001 Company Working Capital Analysis
HANSOH PHARMAC's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
Competition |
In accordance with the company's disclosures, HANSOH PHARMAC HD 00001 has a Working Capital of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The working capital for all Germany stocks is 100.0% higher than that of the company.
Did you try this?
Run Equity Forecasting Now
Equity ForecastingUse basic forecasting models to generate price predictions and determine price momentum |
All Next | Launch Module |
HANSOH Fundamentals
Return On Equity | 0.14 | |||
Return On Asset | 0.063 | |||
Profit Margin | 0.27 % | |||
Operating Margin | 0.28 % | |||
Shares Outstanding | 5.92 B | |||
Shares Owned By Insiders | 81.92 % | |||
Shares Owned By Institutions | 7.99 % | |||
Price To Earning | 38.60 X | |||
Revenue | 9.97 B | |||
Gross Profit | 9.06 B | |||
EBITDA | 3.02 B | |||
Net Income | 2.57 B | |||
Cash And Equivalents | 13.73 B | |||
Cash Per Share | 2.32 X | |||
Total Debt | 92.75 M | |||
Debt To Equity | 0.01 % | |||
Current Ratio | 6.43 X | |||
Book Value Per Share | 3.57 X | |||
Cash Flow From Operations | 2.39 B | |||
Earnings Per Share | 0.06 X | |||
Number Of Employees | 10.78 K | |||
Beta | 0.57 | |||
Market Capitalization | 11.47 B | |||
Z Score | 73.8 | |||
Annual Yield | 0.01 % | |||
Last Dividend Paid | 0.12 |
About HANSOH PHARMAC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HANSOH PHARMAC HD 00001's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HANSOH PHARMAC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HANSOH PHARMAC HD 00001 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in HANSOH Stock
HANSOH PHARMAC financial ratios help investors to determine whether HANSOH Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HANSOH with respect to the benefits of owning HANSOH PHARMAC security.